PMEF
KPTI icon

Point72 Middle East FZE’s Karyopharm Therapeutics KPTI Stock Holding History

Point72 Middle East FZE’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,469
Closed -$19.1K – 728
2023
Q4 		$19.1K Sell
1,469
-4,874
-77% -$65.7K ﹤0.01% 1362
2023
Q3 		$127K Buy
6,343
+614
+11% +$13.8K ﹤0.01% 1100
2023
Q2 		$154K Buy
+5,729
New +$247K ﹤0.01% 1124
2023
Q1 		– Sell
-3,150
Closed -$161K – 1931
2022
Q4 		$161K Buy
+3,150
New +$218K 0.01% 1125

Other funds holding KPTI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Middle East FZE's KPTI Position: Q1 2024 in Review

Point72 Middle East FZE sold out of Karyopharm Therapeutics (KPTI) in Q1 2024, closing a stake of 1,469 shares — an estimated $19.1K sold.

Point72 Middle East FZE first reported a position in KPTI in Q4 2022 and held it in 4 quarters. The position peaked at $161K in Q4 2022. 113 funds tracked by Wall St. Rank hold KPTI as of Q1 2024.

  • Point72 Middle East FZE reported no remaining Karyopharm Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Point72 Middle East FZE sold 1,469 Karyopharm Therapeutics shares in Q1 2024, an estimated $19.1K.
  • Point72 Middle East FZE first reported a position in Karyopharm Therapeutics in Q4 2022 and held it in 4 quarters.
  • Point72 Middle East FZE's Karyopharm Therapeutics position peaked at $161K in Q4 2022.
  • 113 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2024.

Based on Point72 Middle East FZE's 13F filing for Q1 2024.